BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guo M, You C, Dou J. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates. Biomed Pharmacother 2018;107:1318-25. [PMID: 30257347 DOI: 10.1016/j.biopha.2018.08.109] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Lv C, Luo K, Liu S, Zheng M. Fucosyltransferase 4 Predicts Patient Outcome in Rectal Cancer through an Immune Microenvironment-Mediated Multi-Mechanism. Journal of Oncology 2022;2022:1-38. [DOI: 10.1155/2022/4637570] [Reference Citation Analysis]
2 Jia W, Zhang T, Huang H, Feng H, Wang S, Guo Z, Luo Z, Ji X, Cheng X, Zhao R. Colorectal cancer vaccines: The current scenario and future prospects. Front Immunol 2022;13:942235. [DOI: 10.3389/fimmu.2022.942235] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Corrêa LB, Pinto SR, Alencar LMR, Missailidis S, Rosas EC, Henriques MDGMO, Santos-Oliveira R. Nanoparticle conjugated with aptamer anti-MUC1/Y for inflammatory arthritis. Colloids Surf B Biointerfaces 2021;211:112280. [PMID: 34902784 DOI: 10.1016/j.colsurfb.2021.112280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gao XP, Dong JJ, Xie T, Guan X. Integrative Analysis of MUC4 to Prognosis and Immune Infiltration in Pan-Cancer: Friend or Foe? Front Cell Dev Biol 2021;9:695544. [PMID: 34336844 DOI: 10.3389/fcell.2021.695544] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
5 Azadi A, Golchini A, Delazar S, Abarghooi Kahaki F, Dehnavi SM, Payandeh Z, Eyvazi S. Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines. Biol Proced Online 2021;23:13. [PMID: 34193050 DOI: 10.1186/s12575-021-00147-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Tokhanbigli S, Parsamanesh G, Baghaei K, Yarian F, Asadirad A, Hashemi SM, Mohebbi B, Asadzadeh Aghdaei H, Zali MR. Antigenic Potency of LY6E in Stimulating Dendritic Cells to Elicit Tumor-Specific Responses Against Human Colorectal and Gastric Cancer Cell Lines. Int J Pept Res Ther 2021;27:1001-8. [DOI: 10.1007/s10989-020-10145-0] [Reference Citation Analysis]
7 Feng M, Zhao Z, Yang M, Ji J, Zhu D. T-cell-based immunotherapy in colorectal cancer. Cancer Lett 2021;498:201-9. [PMID: 33129958 DOI: 10.1016/j.canlet.2020.10.040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
8 Quaglino E, Cavallo F, Conti L. Cancer stem cell antigens as targets for new combined anti-cancer therapies. Int J Biochem Cell Biol 2020;129:105861. [PMID: 33031926 DOI: 10.1016/j.biocel.2020.105861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Zhang Y, Dong X, Bai L, Shang X, Zeng Y. MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. Oncol Lett. 2020;20:317. [PMID: 33133253 DOI: 10.3892/ol.2020.12180] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li HJ, Wang YL, Ming L, Guo XQ, Li YL, Wang JC, Zhang YQ, Cheng L. Development of a prognostic model based on an immunogenomic landscape analysis of colorectal cancer. Future Oncol 2021;17:301-13. [PMID: 32996773 DOI: 10.2217/fon-2020-0022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Schaft N. The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview. Cancers (Basel) 2020;12:E2567. [PMID: 32916883 DOI: 10.3390/cancers12092567] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 19.5] [Reference Citation Analysis]
12 Guo M, Luo B, Pan M, Li M, Xu H, Zhao F, Dou J. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer. Int Immunopharmacol 2020;88:106850. [PMID: 32777675 DOI: 10.1016/j.intimp.2020.106850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Guo M, Luo B, Pan M, Li M, Zhao F, Dou J. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine. Int Immunopharmacol 2020;85:106631. [PMID: 32470879 DOI: 10.1016/j.intimp.2020.106631] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
14 Kim MJ, Choi JR, Tae N, Wi TM, Kim KM, Kim DH, Lee ES. Novel Antibodies Targeting MUC1-C Showed Anti-Metastasis and Growth-Inhibitory Effects on Human Breast Cancer Cells. Int J Mol Sci 2020;21:E3258. [PMID: 32380650 DOI: 10.3390/ijms21093258] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
15 Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Letters 2019;458:123-35. [DOI: 10.1016/j.canlet.2019.05.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]